Literature DB >> 16214264

Nicotine has a permissive role on the activation of metabotropic glutamate 5 receptors coexisting with nicotinic receptors on rat hippocampal noradrenergic nerve terminals.

Monica Parodi1, Laura Patti, Massimo Grilli, Maurizio Raiteri, Mario Marchi.   

Abstract

The existence of metabotropic glutamate receptors (mGluRs) on hippocampal noradrenergic nerve terminals and their interaction with coexisting nicotinic acetylcholine receptors (nAChRs) were investigated in superfused rat synaptosomes using [(3)H]-noradrenaline ([(3)H]-NA) release as a readout. The selective agonist of group I mGluRs, (S)-3,5-dihydroxyphenylglycine (DHPG), inactive on its own, acquired ability to release [(3)H]-NA when added together with (-)-nicotine. The effect of DHPG was prevented by 2-methyl-6-(phenylethynyl)-pyridine (MPEP), a selective antagonist of mGluR5, but not by 7-(hydroxyimino)cyclopropane[b]chromen-1-carboxylate ethyl ester (CPCCOEt), selective antagonist of mGluR1. The [(3)H]-NA release evoked by (-)-nicotine plus DHPG was totally abrogated by the nAChR antagonist mecamylamine. Veratrine mimicked the permissive role of (-)-nicotine on the activation of mGluR5 mediating [(3)H]-NA release. The mGluR5-mediated component of the [(3)H]-NA release provoked by DHPG plus (-)-nicotine was blocked by xestospongin C, a selective antagonist of inositoltrisphosphate (IP(3)) receptors. It can be concluded that (i) release-enhancing mGluRs of subtype 5 exist on hippocampal noradrenergic axon terminals; (ii) activation of mGluR5 to mediate IP(3)-dependent NA release requires activation of depolarizing nAChRs coexisting on the same terminals.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16214264     DOI: 10.1016/j.neuint.2005.08.010

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  9 in total

Review 1.  Metabotropic glutamate receptor 5 as a potential target for smoking cessation.

Authors:  Cristiano Chiamulera; Claudio Marcello Marzo; David J K Balfour
Journal:  Psychopharmacology (Berl)       Date:  2016-11-16       Impact factor: 4.530

2.  Pre-synaptic nicotinic receptors evoke endogenous glutamate and aspartate release from hippocampal synaptosomes by way of distinct coupling mechanisms.

Authors:  S Zappettini; M Grilli; A Salamone; E Fedele; M Marchi
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

3.  Synaptosomes and Metamodulation of Receptors.

Authors:  Anna Pittaluga; Mario Marchi
Journal:  Methods Mol Biol       Date:  2022

4.  Functional interactions between presynaptic NMDA receptors and metabotropic glutamate receptors co-expressed on rat and human noradrenergic terminals.

Authors:  E Luccini; V Musante; E Neri; M Brambilla Bas; P Severi; M Raiteri; A Pittaluga
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

5.  Presynaptic nicotinic α7 and non-α7 receptors stimulate endogenous GABA release from rat hippocampal synaptosomes through two mechanisms of action.

Authors:  Stefania Zappettini; Massimo Grilli; Federica Lagomarsino; Anna Cavallero; Ernesto Fedele; Mario Marchi
Journal:  PLoS One       Date:  2011-02-08       Impact factor: 3.240

Review 6.  Nicotinic modulation of glutamate receptor function at nerve terminal level: a fine-tuning of synaptic signals.

Authors:  Mario Marchi; Massimo Grilli; Anna M Pittaluga
Journal:  Front Pharmacol       Date:  2015-04-29       Impact factor: 5.810

7.  Anti-allodynic Efficacy of NMDA Antagonist Peptide and Noradrenaline Alone and in Combination in Rodent Neuropathic Pain Model.

Authors:  Farinaz Nasirinezhad; Marjan Hosseini; Sajad Salari
Journal:  Korean J Pain       Date:  2015-04-01

Review 8.  Presynaptic Release-Regulating mGlu1 Receptors in Central Nervous System.

Authors:  Anna Pittaluga
Journal:  Front Pharmacol       Date:  2016-08-31       Impact factor: 5.810

Review 9.  Presynaptic Release-regulating Metabotropic Glutamate Receptors: An Update.

Authors:  Guendalina Olivero; Matteo Vergassola; Francesca Cisani; Alessandra Roggeri; Anna Pittaluga
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.